Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nabumetone
Drug ID BADD_D01511
Description Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action.[A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]
Indications and Usage **Indicated** for:[label] 1) Symptomatic relief in rheumatoid arthritis. 2) Symptomatic relief in osteoarthritis.
Marketing Status approved
ATC Code M01AX01
DrugBank ID DB00461
KEGG ID D00425
MeSH ID D000077430
PubChem ID 4409
TTD Drug ID D05CKR
NDC Product Code 49706-0681; 62331-008; 45865-464; 50090-6167; 60760-369; 60760-386; 62135-145; 0591-3671; 80425-0054; 65977-0082; 50228-465; 51655-733; 62135-146; 63629-8508; 69097-966; 72189-184; 76282-257; 15370-170; 69097-965; 71205-978; 71335-1234; 72189-072; 55700-845; 76420-210; 24196-135; 60687-630; 60760-368; 63187-307; 63629-8506; 69367-241; 69367-242; 0591-3670; 79739-7077; 50090-5386; 50228-466; 53002-6960; 61919-668; 68788-7597; 68788-7765; 79739-7076; 80425-0104; 65015-632; 43063-972; 45865-111; 50090-5294; 51655-446; 60760-387; 63187-378; 63629-7699; 63629-8509; 71335-1272; 71335-1391; 45865-997; 55700-840; 61919-609; 71335-1559; 63629-8510; 76282-258; 80425-0053; 63187-484; 71205-030; 71205-530; 71205-977; 72789-040; 79739-7078
UNII LW0TIW155Z
Synonyms Nabumetone | Nabumeton | 4-(6-Methoxy-2-naphthyl)-2-butanone | Relifex | Relif | Apo-Nabumetone | ApoNabumetone | Mebutan | Listran | Gen-Nabumetone | Arthraxan | BRL 14777 | Rhoxal-nabumetone | Rhoxal nabumetone | Relafen | Nabucox
Chemical Information
Molecular Formula C15H16O2
CAS Registry Number 42924-53-8
SMILES CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tension19.06.02.005---
Thrombocytopenia01.08.01.002---
Thrombophlebitis24.01.02.001---
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Tremor17.01.06.002--
Urticaria10.01.06.001; 23.04.02.0010.000468%
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vasculitis10.02.02.006; 24.12.04.027--
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Tubulointerstitial nephritis20.05.02.0020.000347%-
Hypoacusis04.02.01.0060.000173%
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Haemorrhage24.07.01.002---
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049---
Occult blood positive13.05.02.001---
Nephritic syndrome20.05.01.006---
Acute kidney injury20.01.03.0160.000867%
Liver function test increased13.03.04.031---
Hypersensitivity pneumonitis10.01.03.056; 22.01.01.027---
Renal cell carcinoma stage III16.08.02.015; 20.01.04.0250.000173%-
The 5th Page    First    Pre   5    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene